ONMD PRESS-RELEASE SEC Filing Analysis

Latest settled — T+20d

ONMD ▲ +27.96% at T+20d

NEUTRAL call ✓ call won +27.96% · α vs SPY +18.24% · entry $0.8440 → $1.08

Next anchor: T+60d in 19d

Last close $0.6900 (close Jun 8) · -18.25% from $0.8440 entry

Entry anchored
Mar 31, 02:16 PM ET
via Databento tick

T+1d

+10.19%

call +10.19% · α +10.11%

$0.9300

settled 2mo ago

T+5d

-2.61%

call -2.61% · α -6.37%

$0.8220

settled 2mo ago

T+20d

+27.96%

call +27.96% · α +18.24%

$1.08

settled 6w ago

T+60d

—

call — · α —

—

in 19d

Price Chart

Loading chart...

Executive Summary

OneMedNet announced a pilot collaboration with Inka Health, a subsidiary of Onco-Innovations, granting access to its iRWD™ platform for real-world oncology data analysis. The partnership aims to accelerate development of Onco’s PNKP Inhibitor Technology by identifying rare patient populations and supporting indication expansion. While strategically aligned with OneMedNet’s platform goals, the deal lacks disclosed financial terms or revenue commitments.

Actionable Insight

Monitor for follow-up announcements regarding commercialization of the pilot, expansion of data usage, or additional partnerships. Absent revenue commitments, near-term financial impact is likely minimal despite strategic validation of OneMedNet’s platform.

Key Facts

Inka Health (subsidiary of Onco-Innovations) entered a pilot collaboration with OneMedNet to access its iRWD™ platform.
The collaboration focuses on using real-world data to support development of PNKP Inhibitor Technology for PTEN/SHP1-deficient cancers.
Initial use cases include patient responder identification, indication expansion beyond metastatic colorectal cancer, and enhancing SynoGraph™, an AI platform for predicting cancer treatment success.
The iRWD™ platform is powered by Palantir Foundry and designed to identify rare, molecularly defined patient cohorts.
No financial terms, duration, or revenue commitments were disclosed in the press release.

Financial Impact

Unknown — no financial terms disclosed; potential future revenue depends on pilot conversion to commercial agreement

revenuecustomer acquisition

Risk Factors

Pilot may not convert into a long-term or revenue-generating agreement.
Dependence on third-party success (Onco-Innovations) for downstream value realization.
Limited market visibility due to small partner size and lack of financial disclosure.

Market Snapshot

Exchange

Nasdaq

Sector

Services-Commercial Physical & Biological Research

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3266641

3 reports for ONMD

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for ONMD — sortable, filterable
	Type				Now
Apr 6, 2026 9w ago	Press Release BULLISH ★ 8/10	$0.9520 $1.05	▲ +10.29%	▲ +1.31%	$0.6900 (−27.52%)
Apr 1, 2026 9w ago	Press Release NEUTRAL ★ 4/10	$0.8440 $1.08	▲ +27.96%	▲ +18.24%	$0.6900 (−18.25%)
Mar 18, 2026 11w ago	Press Release MIXED ★ 5/10	$0.8190 $0.8870	▲ +8.30%	▲ +2.26%	$0.6900 (−15.75%)

US Market Status

Market Closed — Opens in 8h 33m

Related Tickers

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access